Timothy F. O'Neill, MD

Dr. Timothy F. O'Neill

Dr. Timothy F. O'Neill joined Los Alamitos Cardiovascular in 1997. Dr. O'Neill is board certified in internal medicine and cardiovascular disease.

 


Dr. Timothy F. O'Neill's Curriculum Vitae

Printable Version View Printable CV
Specialty: Internal Medicine, Cardiology
Board Certifications:
  • Certified in Cardiovascular Disease
    American Board of Internal Medicine
    1993 (Recertification 2009)
  • Certified in Internal Medicine
    American Board of Internal Medicine
    1990
  • National Board Parts I,II,III
    National Board of Medical Examiners
    1985 – 1988
Current Hospital Appointments:
  • Los Alamitos Medical Center
    3751 Katella Avenue
    Los Alamitos, California 90720

  • MemorialCare Health System
    Long Beach Memorial Medical Center

    2801 Atlantic Avenue
    Long Beach, California 90801

  • Lakewood Regional Medical Center
    3700 South Street
    Lakewood, California 90712
Work History:
  • Los Alamitos Cardiovascular/Los Alamitos Internal Group, Inc.
    Cardiologist
    Los Alamitos, California
    February 1997 – Present

  • Heart Institute of the Desert
    Rancho Mirage, California
    October 1993 – February 1997
Education:
  • Pacemaker Fellowship
    Long Beach Memorial Medical Center
    Long Beach, California
    July 1992 – June 1993

  • Cardiology Fellowship
    University of California, Irvine Medical Center
    Irvine, California
    July 1990 – June 1993

  • Internal Medicine Residency
    University of California, Irvine Medical Center
    Irvine, California
    June 1987 – June 1990

  • University of New Mexico School of Medicine
    Doctor of Medicine Degree
    Albuquerque, New Mexico
    August 1983 – May 1987

  • Undergraduate Education
    Creighton University

    Omaha, Nebraska
    Bachelor of Arts Degree in History, Summa Cum Laude
    August 1979 – May 1983
Educational Honors and Awards:
  • Outstanding Intern Commendation
    Veteran's Administration Medical Center
    Long Beach, California
    1987

  • Four Superior Scholastic Achievement Awards
    Creighton University
    1980 – 1983

  • Graduated Summa Cum Laude
    Creighton University
    1983
Clinical Expertise:
  • Non Invasive Cardiology; Echocardiography: TEE, Dobutamine, Stress Echo
  • Invasive Cardiology: Catherization, Permanent Pacemaker Implantation
Research Experience:
  • GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
    Sub-Investigator | 2017
    Sponsor: Amgen
    NCT02929329: https://clinicaltrials.gov/ct2/show/NCT02929329

  • PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
    Sub-Investigator | 2017
    Sponsor: Novartis
    NCT02887183: https://clinicaltrials.gov/ct2/show/NCT02887183

  • Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
    Sub-Investigator | 2016 – Present
    Sponsor: CVRx, Inc.
    NCT02627196: https://clinicaltrials.gov/show/NCT02627196

  • MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
    Sub-Investigator | 2016
    Sponsor: Gilead/ICON

  • THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
    Sub-Investigator | 2015 – Present
    Sponsor: AstraZeneca
    NCT01991795 | https://clinicaltrials.gov/show/NCT01991795

  • Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
    Sub-Investigator | 2015
    Sponsor: Amgen, Evidera

  • DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
    Sub-Investigator | 2013 – Present
    Sponsor: AstraZeneca
    NCT01730534 | http://clinicaltrials.gov/ct2/show/NCT01730534

  • ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
    Sub-Investigator | 2013 – Present
    Sponsor: Sanofi
    NCT01663402 | http://clinicaltrials.gov/ct2/show/NCT01663402

  • SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
    Sub-Investigator | 2013 – 2017
    Sponsor: Yale University School of Medicine/NIH
    NCT01755052 | http://clinicaltrials.gov/ct2/show/NCT01755052

  • RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
    Sub-Investigator | 2013
    Sponsor:  Janssen Scientific Affairs/Johnson & Johnson

  • Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
    Sub-Investigator | 2013
    Sponsor: Tasly Pharmaceuticals
    NCT0169580 | http://clinicaltrials.gov/ct2/show/NCT01659580

  • Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
    Sub-Investigator | 2013 – Present
    Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
    NCT01594333 | http://clinicaltrials.gov/ct2/show/NCT01594333

  • User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.
    Sub-Investigator | 2012
    Sponsor: Alere San Diego

  • Mission® PT Coagulation Monitoring System Clinical Study.
    Sub-Investigator | 2012
    Sponsor: ACON Laboratories, INC.

  • The "BRIDGE" Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
    Sub-Investigator | 2012 – 2015
    Sponsor: National Institutes of Health (NIH) – National Heart, Lung and Blood Institute (NHLBI)
    NCT00786474 | http://clinicaltrials.gov/ct2/show/NCT00786474

  • GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
    Sub-Investigator | 2012 – Present
    Sponsor: Boehringer Ingelheim
    NCT01468701 | http://clinicaltrials.gov/ct2/show/NCT01468701

  • BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
    Sub-Investigator | 2010 – 2012
    Sponsor: St. Jude Medical Center
    NCT01062126 | http://clinicaltrials.gov/ct2/show/NCT01062126

  • The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
    Sub-Investigator | 2010 – 2014
    Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
    NCT01174550 | http://clinicaltrials.gov/ct2/show/record/NCT01174550

  • ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Sub-Investigator | 2010 – Present
    Sponsor: Janssen Scientific Affairs, LLC
    Collaborator: Duke Clinical Research
    NCT01165710 | http://clinicaltrials.gov/ct2/show/NCT01165710
    NCT01701817 | http://clinicaltrials.gov/ct2/show/NCT01701817

  • RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
    NCT00837798 | http://clinicaltrials.gov/ct2/show/NCT00837798

  • FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
    NCT00418314 | http://clinicaltrials.gov/ct2/show/NCT00418314

  • ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation - Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48).
    Sub-Investigator | 2009 – 2015
    Sponsor: Daiichi Sankyo Pharma Development
    NCT00781391 | http://clinicaltrials.gov/ct2/show/record/NCT00781391

Medical Licensure: California, 1989